|
" Tumor targeting in cancer therapy "
edited by Michel Pagé
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
731666
|
| Doc. No
|
:
|
b551452
|
| Main Entry
|
:
|
edited by Michel Pagé
|
| Title & Author
|
:
|
Tumor targeting in cancer therapy\ edited by Michel Pagé
|
| Publication Statement
|
:
|
Totowa, NJ: Springer, 2002
|
| Series Statement
|
:
|
Cancer drug discovery and development.
|
| Page. NO
|
:
|
(x, 463 pages .)
|
| ISBN
|
:
|
1592591671
|
|
|
:
|
: 9781592591671
|
| Contents
|
:
|
Part I. A Review The Current Status of Tumor Targeting: A Review Tarunendu Ghose Clinical Applications of Targeted Therapeutics Tarunendu Ghose Part II. Targeting Tumors with Drug Antibody Conjugates Targeting the CD22 Receptor with RNA Damaging Agents Huaitian Liu, Dianne L. Newton, Hans J. Hansen, Stanislaw M. Mikulski, David M. Goldenberg, Edward A. Sausville, and Susanna M. Rybak The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors Paul Tardi, Ludger Ickenstein, Marcel Bally, and Lawrence Mayer Overcoming Multiple Drug Resistance with Anti-Pgp Carrier Brigitte Page and Michel Page Targeting with Transferrin, Mandip Singh Synthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In Vitro Jairo Jaime Correa and Michel Page The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer Geoffrey A. Pietersz and Ian F. C. McKenzie Part III. Targeting Tumors with Antibodies Targeting Vascular Endothelium with Antibodies Przemek Twardowski and Kim Margolin Targeting B-Cell Non-Hodgkin's Lymphoma with Monoclonal Antibodies Christian Buske and W. Hiddemann From Bench to Bedside: Development of Rituximab (Rituxan (R)), A Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma Roland Newman Mylotarg: The First Antibody-Targeted Chemotherapy Agent Philip R. Hamann and Mark S. Berger Part IV. Targeting Tumors with Radioimmunoconjugates 188Rhenium-Labeled Trisuccin-DCh2HuCC49 as a Radioimmunotherapy Model in Nude Mice Ahmad Safavy and Donald J. Buchsbaum Part V. Targeting Tumors with Immunotoxins General Approach for Targeting Toxins Manish Monga, Richard A. Messman, and Edward A. Sausville Antibody-Toxin Conjugates: Chemistry of Couplingand Purification Silvana Canevari, Maria Ines Colnaghi, Luigi Cattel, and Franco Dosio Shiga-Like Toxins as Targeted Anticancer Agents Paul LaPointe and Jean Gariepy Part VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT) Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies Kenneth D. Bagshawe Part VII. Photodynamic Therapy Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates Cynthia M. Allen, Wesley M. Sharman, and Johan E. van Lier Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model Rene Hornung Part VIII. Targeting Tumors with Magnetic Drugs Targeting Tumors with Magnetic Drugs Andreas S. Lubbe, Christian Bergemann, and Christoph Alexiou Part IX. Principles and Techniques in Targeting Internalization of Antibodies Jairo Jaime Correa Bioconjugation and Biodistribution Francesco M. Veronese and Paulo Caliceti Principles of Antitumor Targeting of Cytotoxic Drugs Gene M. Dubowchik Targeting by Antibody or Ligand: Which Is Better? Douglas A. Lapp Index
|
| Abstract
|
:
|
After many years of vigorous effort, the use of antibodies to target tumors has become highly successful both clinically and commercially. In Tumor Targeting in Cancer Therapy, Dr. Michel Pag? and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand. Comprehensive and practical, Tumor Targeting in Cancer Therapy summarizes the essentials of tumor targeting as it is practiced today and provides all those engaged in experimental and clinical cancer research the critically established information needed to evaluate new technologies, investigate novel therapeutic agents, and apply them in relevant clinical practice.
|
| Subject
|
:
|
Cancer -- Chemotherapy.
|
| Subject
|
:
|
Cancer -- Immunotherapy.
|
| Subject
|
:
|
Drug targeting.
|
| Added Entry
|
:
|
Michel Pagé
|
| |